Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS0612 in Advanced Solid Tumors
NCT04586270Phase 1Terminated
- Sponsor
- Taiho Oncology
- Start
- Oct 2020
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of tas0612 in solid tumor and prostate cancer (PCa) (2 arms), sponsored by Taiho Oncology. Primary endpoints: Dose Limiting Toxicities at 28 days and Radiographic Progression Free Survival rate at 12 months. Started Oct 2020; status: terminated.
02
Drugs
tas0612
03
Conditions
solid tumorprostate cancer (PCa)
Beyond the preview
Go deeper on NCT04586270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04586270.